BACLOFEN-20 TABLET
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
10-03-2021
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
BACLOFEN
Tillgänglig från:
PRO DOC LIMITEE
ATC-kod:
M03BX01
INN (International namn):
BACLOFEN
Dos:
20MG
Läkemedelsform:
TABLET
Sammansättning:
BACLOFEN 20MG
Administreringssätt:
ORAL
Enheter i paketet:
100
Receptbelagda typ:
Prescription
Terapiområde:
GABA-DERIVATIVE SKELETAL MUSCLE RELAXANTS
Produktsammanfattning:
Active ingredient group (AIG) number: 0113246002; AHFS:
Bemyndigande status:
APPROVED
Tillstånd datum:
2019-01-15
Produktens egenskaper
Page 1 of 27
PRODUCT MONOGRAPH
PR
BACLOFEN – 10
PR
BACLOFEN – 20
BACLOFEN TABLETS USP
10 MG AND 20 MG
ANTISPASTIC AGENT
PRO DOC LTÉE
DATE OF REVISION:
2925, boul. Industriel
March 10, 2021
Laval, Quebec
H7L 3W9
Control Number: 248887
Page 2 of 27
TABLE OF CONTENT
THERAPEUTIC CLASSIFICATION
...........................................................................................................................
3
CLINICAL PHARMACOLOGY
....................................................................................................................................
3
INDICATIONS
...............................................................................................................................................................
5
CONTRAINDICATIONS
...............................................................................................................................................
5
WARNINGS
...................................................................................................................................................................
5
PRECAUTIONS
............................................................................................................................................................
9
ADVERSE REACTIONS
.............................................................................................................................................12
SYMPTOMS AND TREATMENT OF OVERDOSAGE
..........................................................................................14
DOSAGE AND ADMINISTRATION
..........................................................................................................................15
AVAILABILITY
..............................................................................................................................................................17
CHEMISTRY AND PHARMACOLOGY
....................................................................................................................18
PHARMACOLOGY
.........
Läs hela dokumentet
